MIAMI, April 22, 2021 (GLOBE NEWSWIRE) – Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapies to the psychedelic and mental health industries, today announced that the company was ahead of schedule and plans to launch KetaDASH IV ketamine therapy www.ketadash.com by the end of the second trimester. In a press release dated February 26, 2021, Ehave announced plans to launch open trials of its ketamine IV therapy KetaDASH in the second trimester. Ehave hired a legal advisor to advise the company on the deployment of KetaDASH. Ehave has also obtained an umbrella policy to cover liability and malpractice insurance on each door-to-door delivery service. In the next 60 days, KetaDASH plans to start enrolling clients and start referring to local clinics. Ehave is currently in negotiations with several entities to franchise the KetaDASH platform or purchase a license across the United States.
The KetaDASH platform allows licensed ketamine clinics and patients prescribed ketamine by a doctor to administer home treatment intravenously. This gives the clinic the opportunity to increase its revenue by treating patients who cannot make it to their office. KetaDASH will provide the platform for medical practitioners to administer ketamine intravenously to patients at home. Ketamine is currently used to help relieve pain and allows sedatives to be effective at lower doses, thereby reducing the amount of potentially addicting pain relievers needed after certain medical procedures. Ketamine is currently being studied as a treatment for major depression, although it has not yet been approved by the FDA to treat depression.
KetaDASH is a personalized mental care platform designed to instantly connect patients with highly trained nurses to deliver ketamine therapy at home under expert supervision. The platform has been strategically designed as a smart and intuitive dashboard from which patients and their associated nurses can obtain detailed information about treatments. The KetaDASH platform will include software, personnel, protocols and hardware. Ehave has designed a smart and intuitive dashboard for KetaDASH from which clients and associated nurses can get detailed information on how ketamine therapy works. Patients will be able to create a profile, check the availability of nurse administrators and schedule appointments.
KetaDASH has entered into an agreement with Vein-Eye Carry to use its infrared imaging technology. Every day, there are 30 to 40 million venipunctures in the world and about 3 million in the United States. Treatment delays can occur in about 25 percent of all patients due to the inability to establish IV access, or “find a vein,” as it is more commonly known. One in three attempts to establish IV access is unsuccessful in adults, and one in two attempts fails in pediatrics. In critically ill patients, the venipuncture failure rate ranges from 10% to 40% where venipuncture is more difficult.
“Cutting-edge technology is going to be the next wave in the way we receive healthcare,” said Alfred Farrington II, CIO of Ehave. Mr Farrington continued, “The next wave of innovation in healthcare is the evolution of ecosystems. KetaDASH has the capacity to change the lives of those with mental health issues.”
Ehave CEO Ben Kaplan said, “Our continued dedication and commitment to mental health makes KetaDASH a reality. Many patients who need ketamine therapy are homebound. KetaDASH gives us the ability to provide ketamine as an assisted psychedelic therapy for individuals suffering from depression, anxiety, post-traumatic stress, or other mental or emotional health issues. KetaDASH will not only provide infusion therapy. of ketamine potentially vital for the treatment of psychiatric disorders, but will also provide Ehave with the opportunity to create a platform for income generation.
Additional Information about Ehave Inc.
We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter telegram group at https://t.me/EhaveInc.
The company posts important information and updates via weekly videos on the company’s official YouTube channel. https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
Please follow Ehave on Twitter @ Ehaveinc1
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a leader in digital therapeutics providing evidence-based therapeutic interventions to patients. Our main goal is to improve standard therapeutic care to prevent or treat brain disorders or diseases through the use of digital therapies, independently or in conjunction with drugs, devices and other therapies to optimize care. to patients and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health computing platform that enables clinicians to make objective and intelligent decisions through data insight. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its key partners. This enables patients, healthcare providers and payers to treat a wide range of conditions through high-quality, safe and efficient data-driven engagement with smart and accessible tools. Additional information about Ehave is available on the Company’s website at: www.ehave.com.
Disclaimer Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of
Securities Litigation Reform Act of 1995. These statements may be preceded by the words
“Intends”, “can”, “will”, “plans”, “waits”, “anticipates”, “plans”, “predicts”, “estimates”, “aims”, “believes”, “hopes” , “Potential” Or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company and cannot be predicted or quantified and, therefore, actual results may differ materially from those expressed or implied by these forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacture, development, marketing and market acceptance of the Company’s products; (iv) lack of sufficient funding to finance product development and business operations; (v) competitive businesses and technologies within the Company’s industry and the introduction of competitive products; (vi) the company’s ability to establish and maintain corporate collaborations; (vii) the loss of key managers; (viii) the extent of protection that the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential non-compliance with applicable health information privacy and security laws and other federal and state privacy and security laws; and (x) the difficulty of predicting the actions of the US FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, except as required by law. More detailed information about the company and the risk factors that may affect the making of forward-looking statements are contained under “Risk Factors” in the registration of Ehave, Inc.
Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on
September 24, 2015, as amended, available on the SEC website, http://www.sec.gov.
Media inquiries: Gabe Rodriguez
Email: [email protected]
Telephone: (623) 261-9046